AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26375841 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFIPs (multifactorial intervention programs) including health education, weight-reduction/control program, quadriceps exercise training class, home-based exercise program, and home visit program
Number of subjects: 80
Study 26375841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MUFIPs)
Number of subjects: 80
Study 23150043 — intervention group
Group type: EXPERIMENTAL
Intervention: DRAMA‐RAMA
Number of subjects: 44
Study 23150043 — intervention group
Group type: COMPARATOR
Intervention: Wii Dancing With the Stars
Number of subjects: 44
Study 22145256 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane coasting (in O2/air)
Number of subjects: 69
Study 19853417 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 72
Study 19853417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19853417 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and Placebo
Number of subjects: 72
Study 16903245 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser CO2 surgery during pregnancy
Number of subjects: 280
Study 16903245 — intervention group
Group type: COMPARATOR
Intervention: Postpartum treatment (three months after delivery)
Number of subjects: 280
Study 15039256 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical training
Number of subjects: 52
Study 15039256 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 52
Study 15039256 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosis
Number of subjects: 52
Study 11884000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral multivitamins from the first day of admission
Number of subjects: 1561
Study 11884000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally complete sipfeed from the second day in 'thin' patients
Number of subjects: 1561
Study 9462474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tau concentrations
Number of subjects: 43
Study 9462474 — intervention group
Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein (GFAP) expression
Number of subjects: 43
Study 7894959 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise repeated 48 hours after initial bout (Group 2)
Number of subjects: 26
Study 7894959 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (Group 2)
Number of subjects: 26
Study 7894959 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 26
Study 2955324 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1 mg/kg
Number of subjects: 63
Study 2955324 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 63
Study 2955324 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (both dosages)
Number of subjects: 63
Study 30081951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 137
Study 26460504 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r) 800/100 mg once daily for 48 weeks
Number of subjects: 64
Study 26460504 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r)
Number of subjects: 64
Study 26460504 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 64
Study 24329424 — intervention group
Group type: EXPERIMENTAL
Intervention: CASA intervention (Collaborative Care to Alleviate Symptoms and Adjust to Illness)
Number of subjects: 17
Study 22739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 15 μg/d (D3-15)
Number of subjects: 394
Study 22739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10 μg/d (D3-10)
Number of subjects: 394
Study 22739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5 μg/d (D3-5)
Number of subjects: 394
Study 22739371 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 0 μg/d (P)
Number of subjects: 394
Study 22739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (any dose)
Number of subjects: 394
Study 22739371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fok I ff genotype
Number of subjects: 394
Study 20842967 — intervention group
Group type: EXPERIMENTAL
Intervention: Consciously perceived prime
Number of subjects: 0
Study 20842967 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconsciously perceived prime
Number of subjects: 0
Study 18479176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam quick-release tablet (QR)
Number of subjects: 18
Study 18479176 — intervention group
Group type: COMPARATOR
Intervention: Lornoxicam standard tablet (ST)
Number of subjects: 18
Study 18479176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam intramuscular injection (IM)
Number of subjects: 18
Study 16140282 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean 11.30 mg/day)
Number of subjects: 263
Study 16140282 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean 4.87 mg/day)
Number of subjects: 263
Study 14578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide at -15 min
Number of subjects: 40
Study 14578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide at 0 min
Number of subjects: 40
Study 14578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide at +15 min
Number of subjects: 40
Study 14578242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide at +30 min
Number of subjects: 40
Study 14578242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11885177 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 2973
Study 11885177 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 2973
Study 9151584 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard machined titanium abutment (R(a) = 0.2 microns)
Number of subjects: 6
Study 9151584 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly polished ceramic abutment (R(a) = 0.06 microns)
Number of subjects: 6
Study 9151584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both abutments
Number of subjects: 6
Study 1422754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomoparan (750 anti-Xa units subcutaneously twice a day)
Number of subjects: 309
Study 1422754 — intervention group
Group type: COMPARATOR
Intervention: Heparin-DHE 5000 (5000 units heparin and 0.5 mg dihydroergotamine subcutaneously twice a day)
Number of subjects: 309
Study 1422754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomoparan
Number of subjects: 309
Study 1422754 — intervention group
Group type: COMPARATOR
Intervention: Heparin-DHE 5000
Number of subjects: 309
Study 6708033 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 54
Study 6708033 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 54
Study 6708033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose in lactated Ringer's solution)
Number of subjects: 54
Study 30753303 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach rehabilitation program (10 weeks, 30 sessions)
Number of subjects: 77
Study 30753303 — intervention group
Group type: COMPARATOR
Intervention: Control (usual posthospital fracture care)
Number of subjects: 77
Study 29975203 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fascia iliaca block with 40 ml ropivacaine 0.2%
Number of subjects: 80
Study 29975203 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study 27129477 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive, couple‐ and parenting‐focused program designed to prevent stress‐spillover (n=70)
Number of subjects: 139
Study 27129477 — intervention group
Group type: COMPARATOR
Intervention: Information‐only control condition (n=69)
Number of subjects: 139
Study 24670048 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal music (high and low intensity combined)
Number of subjects: 226
Study 24670048 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music (high and low intensity combined)
Number of subjects: 226
Study 24670048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no background music)
Number of subjects: 226
Study 24670048 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal music
Number of subjects: 226
Study 24670048 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 226
Study 22226132 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter without extension tubing (group 1)
Number of subjects: 121
Study 22226132 — intervention group
Group type: COMPARATOR
Intervention: IV catheter with extension tubing (group 2)
Number of subjects: 121
Study 22226132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' predictions of hemolysis
Number of subjects: 121
Study 20337873 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhead illumination (group 1)
Number of subjects: 242
Study 20337873 — intervention group
Group type: COMPARATOR
Intervention: Underneath illumination (group 2)
Number of subjects: 242
Study 19087702 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 1857
Study 19087702 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 1857
Study 16123896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 800 mg p.o. with standardized meal (Biloptin, 40 gs)
Number of subjects: 20
Study 16123896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone i.v. with standardized meal (Biloptin, 40 gs)
Number of subjects: 20
Study 16123896 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standardized meal (Biloptin, 40 gs)
Number of subjects: 20
Study 16123896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone p.o. and i.v. with standardized meal (Biloptin, 40 gs)
Number of subjects: 20
Study 12893113 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antiepileptic drugs used to treat seizure disorder
Number of subjects: 0
Study 12893113 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of intractable epilepsy
Number of subjects: 0
Study 12893113 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical and uncontrolled data
Number of subjects: 0
Study 10393134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk fat intake
Number of subjects: 123
Study 8857217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry test
Number of subjects: 100
Study 8857217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mile run
Number of subjects: 100
Study 1995721 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine (10^4 pfu)
Number of subjects: 321
Study 1995721 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 vaccine (10^8 pfu)
Number of subjects: 321
Study 1995721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 6089304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 4 weeks
Number of subjects: 24
Study 6089304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6089304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 24
Study 30846465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 30846465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28569647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed depression help-seeking messages
Number of subjects: 153
Study 28569647 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed depression help-seeking messages
Number of subjects: 153
Study 26786346 — intervention group
Group type: EXPERIMENTAL
Intervention: FORTA intervention (instruction on FORTA by a FORTA team)
Number of subjects: 409
Study 26786346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FORTA intervention)
Number of subjects: 409
Study 24262102 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-ultrasound fusion biopsy
Number of subjects: 125
Study 24262102 — intervention group
Group type: COMPARATOR
Intervention: Visual targeting
Number of subjects: 125
Study 24262102 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsy
Number of subjects: 125
Study 22575075 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pregabalin
Number of subjects: 38
Study 22575075 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pregabalin
Number of subjects: 38
Study 22575075 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg pregabalin
Number of subjects: 38
Study 22575075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg pregabalin
Number of subjects: 38
Study 22575075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22575075 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 38
Study 20627696 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 154
Study 20627696 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 154
Study 20627696 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 154
Study 17436845 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy using a sensory integration approach (OT‐SI)
Number of subjects: 24
Study 17436845 — intervention group
Group type: COMPARATOR
Intervention: Activity Protocol
Number of subjects: 24
Study 17436845 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 24
Study 15821119 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic Protocol (AP)
Number of subjects: 0
Study 15821119 — intervention group
Group type: COMPARATOR
Intervention: Physician Discretion (PD)
Number of subjects: 0
Study 11287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lines Cancellation (LC) task
Number of subjects: 148
Study 11287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Features Targets Cancellation (MFTC) task
Number of subjects: 148
Study 11287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Execution time for LC and MFTC tasks
Number of subjects: 148
Study 11287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Deterioration Battery (MDB)
Number of subjects: 148
Study 9646878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 125
Study 9646878 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 125
Study 7836622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched with magnesium for 6 days
Number of subjects: 58
Study 7836622 — intervention group
Group type: COMPARATOR
Intervention: Three different magnesium oxide preparations
Number of subjects: 58
Study 2873966 — intervention group
Group type: EXPERIMENTAL
Intervention: Endralazine (10 mg to 30 mg per day)
Number of subjects: 30
Study 2873966 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (75 mg to 200 mg per day)
Number of subjects: 30
Study 2873966 — intervention group
Group type: EXPERIMENTAL
Intervention: Endralazine
Number of subjects: 30
Study 29035134 — intervention group
Group type: EXPERIMENTAL
Intervention: HALNo
Number of subjects: 30
Study 29035134 — intervention group
Group type: COMPARATOR
Intervention: LNo
Number of subjects: 30
Study 27197920 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical cystectomy with intracorporeal diversion (iRARC)
Number of subjects: 82
Study 24372795 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility-enhanced multimedia informational education
Number of subjects: 123
Study 24372795 — intervention group
Group type: COMPARATOR
Intervention: Regular education
Number of subjects: 123
Study 24372795 — intervention group
Group type: COMPARATOR
Intervention: Instructional digital videodisc education
Number of subjects: 123
Study 23203206 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified shoes
Number of subjects: 90
Study 23203206 — intervention group
Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 90
Study 23203206 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 90
Study 22003158 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented, motor sequence learning exercise (TO)
Number of subjects: 47
Study 22003158 — intervention group
Group type: COMPARATOR
Intervention: Impairment-oriented, multicomponent exercise (IO)
Number of subjects: 47
Study 18433678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US)
Number of subjects: 74
Study 18433678 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (group NS)
Number of subjects: 74
Study 16931259 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 0.0125% solution (Group 1, n = 20)
Number of subjects: 40
Study 16931259 — intervention group
Group type: COMPARATOR
Intervention: No anterior capsule staining (Group 2, n = 20)
Number of subjects: 40
Study 12971634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (ChT)
Number of subjects: 23
Study 12971634 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 201Tl ratios
Number of subjects: 23
Study 12971634 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed 201Tl uptake
Number of subjects: 23
Study 10870068 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer bandaging followed by elastic hosiery
Number of subjects: 90
Study 10870068 — intervention group
Group type: COMPARATOR
Intervention: Hosiery alone
Number of subjects: 90
Study 9090608 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic MRI examination using a special device for incremental passive positioning of the ankle.
Number of subjects: 12
Study 8257196 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured cognitive‐behavioral group intervention
Number of subjects: 3
Study 8257196 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 3
Study 8257196 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 3
Study 7107688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 201
Study 7107688 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 201
Study 31794610 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0
Study 31794610 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 29350775 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (1mA, 20 minutes)
Number of subjects: 60
Study 29350775 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 26832736 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa plus usual provision
Number of subjects: 0
Study 26832736 — intervention group
Group type: COMPARATOR
Intervention: Usual provision only
Number of subjects: 0
Study 24845173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 24845173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22916226 — intervention group
Group type: EXPERIMENTAL
Intervention: Closantel treatment at dry-off
Number of subjects: 402
Study 19147504 — intervention group
Group type: EXPERIMENTAL
Intervention: HSA+serum substitute supplement (SSS)
Number of subjects: 528
Study 19147504 — intervention group
Group type: COMPARATOR
Intervention: HSA (as the sole protein supplement)
Number of subjects: 528
Study 17971178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (<= 40 g carbohydrate/day)
Number of subjects: 26
Study 17971178 — intervention group
Group type: COMPARATOR
Intervention: Healthy-eating diet following Diabetes UK nutritional recommendations
Number of subjects: 26
Study 17971178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 26
Study 17971178 — intervention group
Group type: COMPARATOR
Intervention: Healthy-eating diet
Number of subjects: 26
Study 16792539 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐I alpha‐2b 1.0 microg/kg BW
Number of subjects: 227
Study 15609594 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu decoction (XZD) with conventional liver protective treatment
Number of subjects: 60
Study 15609594 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver protective treatment alone
Number of subjects: 60
Study 10391548 — intervention group
Group type: COMPARATOR
Intervention: Conventional cementing technique
Number of subjects: 60
Study 10391548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-vacuum cementing technique
Number of subjects: 60
Study 10391548 — intervention group
Group type: EXPERIMENTAL
Intervention: No cement fixation
Number of subjects: 60
Study 8895147 — intervention group
Group type: EXPERIMENTAL
Intervention: DP-1904 (400 mg/day bid)
Number of subjects: 8
Study 8895147 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg/day bid)
Number of subjects: 8
Study 1806334 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate 300 mcg/day
Number of subjects: 22
Study 1806334 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 6354522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) infusion during low sodium intake (10 mmol)
Number of subjects: 8
Study 6354522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) infusion during high sodium intake (200 mmol)
Number of subjects: 8
Study 30610213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg curcumin
Number of subjects: 52
Study 30610213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28662296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 30
Study 28662296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26134371 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline therapy
Number of subjects: 106
Study 23630185 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% expectancy of receiving levodopa
Number of subjects: 26
Study 23630185 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% expectancy of receiving levodopa
Number of subjects: 26
Study 23630185 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% expectancy of receiving levodopa
Number of subjects: 26
Study 23630185 — intervention group
Group type: COMPARATOR
Intervention: Placebo levodopa (all subjects)
Number of subjects: 26